Dr. Constance Zou MD
I’m a board certified psychiatrist with dedicated training and extensive experience treating depression, anxiety, intrusive thoughts, trauma, women’s reproductive mental health, and sleep-related issues. I utilize both psychoanalytic and cognitive-based psychotherapy modalities to provide personalized care tailored to your unique needs.
With over a decade of continuous engagement in medical research, I am passionate about delivering evidence based care and advancing the field of psychiatry. Part of my previous work highlighted biases and inaccuracies in the publication of clinical trials by pharmaceutical companies, emphasizing the importance of informed and safe treatment choices.
At our practice, you will find a compassionate and knowledgeable partner in your mental health journey. Together, we will work towards achieving your personal goals and enhancing your overall well-being.
Education
MD, Yale School of Medicine, New Haven, CT
MA in Bioethics, New York University, New York, NY
BA in Biology, Summa Cum Laude, Phi Beta Kappa, Honors Society, Columbia University, New York, NY
Residency and Fellowship
General Psychiatry, Medical University of South Carolina, Charleston, SC and National Institute of Mental Health, Bethesda, MD.
Clinical Fellowship, National institute of Mental Health, Bethesda, MD
Board Certification
American Board of Psychiatry and Neurology
Conference Presentations
Zou CX, Ben-Dor R, Guerrieri GM, Martinez PE, McCluggage P, Ben-Dor Y, Nieman LK, Wakim P, Rubinow DR, Schmidt PJ. Depression and Menopausal Transition: a Prospective Longitudinal Study. Poster, Society of Biological Psychiatry 2023 April 26 th -29 th , San Diego, CA.
Zou CX, Becker JE, Phillips AT, Krumholz HM, Miller JE, Ross JS. Impact of FDAAA on Registration, Results Reporting and Publication of Neuropsychiatric Clinical Trials Supporting FDA New Drug Approval, 2005-2014. Podium Presentation, 2017, Eighth Peer Review Congress, Chicago, IL
Basturk O, Wei JJ, Kong J, Zou X*, Peng Y, Melamed J, Lee P. MicroRNA Expression in Androgen Independent and Metastatic Prostate Cancer. In: Proceedings of the United States and Canadian Academy of Pathology Annual Meeting 2008, 2008 March 1-7. Denver, CO
Newman KK, Wang BY, Cetin N, Ye H, Zou X*, Lee P, Melamed J. Differential Steroid Hormone Expression in Renal Cell Carcinoma Subtypes. In: Proceedings of the United States and Canadian Academy of Pathology Annual Meeting 2009. March 7-13. Boston, MA
Pan LY, Wei JJ, Patwa RR, Ligr M, Jain S, Zou XY*, Daniels G, Li YR, Xu RL, Sun W, Wang ZX, Lee P, Chen F. Androgen Receptor Coactivator p44/Mep50 in Ovarian Cancer. In: Proceedings of the United States and Canadian Academy of Pathology Annual Meeting 2010. March 20-26, Washington DC
Peer-Reviewed Publications
Zou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials 2018 Oct 23;19(1):581
Phillips AT, Desai, NR, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials. 2017 July 18:333
Segura MF, Hanniford D, Menendez S, Reavie L, Zou X*, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9.
Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X*, Pellicer A, Garabedian MJ, Ferrari A, Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009 Apr 15;69(8):3332-8.
Shi G, Perle MA, Mittal K, Chen H, Zou X*, Hernando E, Lee P, Wei JJ. J Cell Mol Med. 2008 Oct 13. Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. J Cell Mol Med. 13(9B):3898-905 2008 Oct 13.
Peng Y, Li Y, Gellert LL, Zou X*, Wang J, Singh B, Xu R, Chiriboga L, Daniels G, Pan R, Zhang DY, Garabedian M, Schneider R, Wang Z, Lee P. Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med. 2009 Oct 16.
Wang L, Zou X*, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 2009;1(1):62-71.
Ligr M, Li Y, Zou X*, Daniels G, Melamed J, Peng Y, Wang W, Wang J, Ostrer H, Pagano M, Wang Z, Garabedian MJ, Lee P. Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol. 2010 Apr;176(4):1891-900.
Hatcher DL, Daniels G, Lin L, Basturk O, Zou X, Ostrer H, Epithelial and stromal microRNA expression in racial disparity of prostate cancer. J Urology. 2009 April;181(4) Supplement773–774
Mahajan A, Liu Z, Gellert L, Zou X*, Yang G, Lee P, Yang X, Wei JJ. HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol. 2010 May;23(5):673-81.
Monaco ME, Creighton CJ, Lee P, Zou X*, Topham MK, Stafforini DM. Expression of long-chain fatty acyl-coA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity. Transl Oncol. 2010 Apr;3(2):91-8.
Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X*, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee P.Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer. Breast Cancer Res Treat. 2011 Jul;128(2):391-400.
Wang L, Zou X*, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. 2009;1(1):62-71.
* Published under previous legal name Zou, Xuanyi